CNST News and Press, Constellation Pharmaceuticals Inc. From 10/29/20

Gainers: Universal Security Instruments (UUU) +69%.Polar Power (POLA) +37%.Rekor Systems (REKR) +35%.Entercom Communications (ETM) +33%.Pinterest (PINS) +29%.Inphi (IPHI) +28%.Forte Biosciences (FBRX) +21%.Meta Financial Group (CASH) +19%.Novus Therapeutics (NVUS) +18%.Dig...

Gainers: vTv Therapeutics (VTVT) +22%, Forte Biosciences (FBRX) +20%, Penumbra (PEN) +14%, Cellect Biotechnology (APOP) +10%, Inari Medical (NARI) +10%.Losers: Tricida (TCDA) -52%, Cancer Genetics (CGIX) -34%., Constellation Pharmaceutica...

The following slide deck was published by Constellation Pharmaceuticals, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Constellation Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation

Constellation Pharmaceuticals (CNST): Q3 GAAP EPS of -$0.71 misses by $0.02.Cash equivalents and marketable securities of $489.4M.Press Release For further details see: Constellation Pharmaceuticals EPS misses by $0.02

MANIFEST d ata update planned for the American Society of Hematology (ASH) meeting in December CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetic...

CAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on October 29, 2020, to discuss ...

Constellation's lead candidate CPI-0610 has shown efficacy as a potential monotherapy or combo treatment alongside Jakafi, against myelofibrosis in a phase 2 trial. The BET-inhibitor is scheduled to enter a pivotal phase 3 trial in H220, with similar endpoints - spleen reduction volum...

In a note RBC regards yesterday's selloff in biotechs as an "especially attractive entry point" for leading names such names as Gilead Sciences ([[GILD]] -2.1%), Sarepta Therapeutics ([[SRPT]] -1.8%) and Constellation Pharmaceuticals ([[CNST]] -5.0%).Analysts, led by Brian Abrahams, believe G...

CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in up...

Oppenheimer analyst Silvan Tuerkcan has downgraded Constellation Pharmaceuticals ( CNST -4.0% ) to Perform from Outperform, and lowered price target to $20 from $47 driven by new 25% Probability of Success versus prior 60% for its lead asset CPI-0610, in myelofibrosis, a rare bone marrow c...